相关实验视频

Updated: Jan 18, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

DPP4抑制剂西塔利普丁对中铁的作用

Baohua Hou^1,2, Lin Li¹, Fei Wang¹

¹Central Laboratory, The First Affiliated Hospital of Henan Polytechnic University (Jiaozuo Second People's Hospital), 454001 Jiaozuo, Henan, China.

Journal of integrative neuroscience

|September 8, 2025

概括

在模型中,Dipeptidyl Peptidase-4 (DPP4) 抑制剂西塔格利普丁通过减轻铁死来降低发作严重程度和型活动. 这项研究揭示了管理的潜在新治疗点.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
细胞生物学细胞生物学

背景情况:

是一种神经系统疾病,其特点是经常性发作,这对健康构成重大挑战.
双基化酶-4 (DPP4) 抑制剂显示出潜在的抗性质.
铁,一种编程细胞死亡的形式,是的新兴治疗目标.

研究的目的:

为了研究DPP4抑制剂的抗机制,特别是西塔利普丁.
探索铁病在西塔利普丁对的治疗效果中的作用.
评估西塔利普丁对神经元铁亡标记物的影响.

主要方法:

使用LiCl/Pilocarpine诱导的的小鼠模型进行EEG和行为评估.
分析了公共RNA测序数据,以确定与有关的目标.
在老鼠模型中评估神经元铁死和使用西式涂抹和免疫光检测诱导的谷氨酸神经元细胞.

主要成果:

在模型中,西塔格利普丁显著降低了发作严重程度和型活动.
西塔格利普丁降低了血氧酶-1 (HO-1),活性氧物种 (ROS) 和线粒体损伤.
西塔利普丁在动物和细胞模型中增加了谷氨过氧化酶4 (GPX4) 表达,这表明铁亡的缓解.

结论:

在模型中,西塔格利普丁有效地减轻了铁.
这些发现表明DPP4抑制剂,如西塔格利普丁,为提供了一个有前途的治疗策略.
这项研究强调了铁质作为新型治疗的关键标.

关键词:

双基酸酶-4的二基酸.是一种.铁性化 (ferroptosis) 是一种谷氨过氧化酶4的作用血红氧酶-1-1的使用

更多相关视频

A Low-cost Method for Analyzing Seizure-like Activity and Movement in Drosophila

A Low-cost Method for Analyzing Seizure-like Activity and Movement in Drosophila

Published on: February 19, 2014

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Necrosis

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...